Hermann V.
- Country
- Germany
- Department
- Obstetrics and Gynecology
Research Overview
- Efficacy and Safety of Inavolisib plus Combination Therapy in Patients with Endocrine-Resistant HR+/HER2- Advanced Breast Cancer with Chromosome 8p Loss
- Comparison of RO7771950 plus combination therapy versus tucatinib plus combination therapy in pretreated HER2-positive locally advanced or metastatic breast cancer
- CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCER PATIENTS
Data & Insights
Has run more than one trial at 358 of 691 partner sites.
Specializations
Breast Cancer Specialization
Focuses on advancing treatment approaches for various forms of breast cancer, with particular emphasis on hormone receptor-positive and HER2-positive/negative variants.
- Early-stage breast cancer treatment
- Advanced and metastatic breast cancer management
- Triple-negative breast cancer interventions
Investigates innovative therapeutic combinations including targeted therapies and immunotherapy approaches.
Endocrine Therapy Research
Specializes in hormone-dependent cancer treatments, focusing on novel therapeutic approaches for estrogen receptor-positive cancers.
- Endocrine resistance mechanisms
- Combination therapy strategies
- Novel endocrine agents evaluation
Explores innovative treatment combinations with targeted therapies and immune checkpoint inhibitors.
Gynecologic Oncology
Conducts research in advanced gynecologic malignancies, with specific focus on ovarian cancer and endometrial cancer treatments.
- Advanced ovarian cancer therapies
- Endometrial cancer interventions
- Maintenance treatment strategies
Evaluates novel therapeutic approaches including immunotherapy and targeted agents for gynecologic cancers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.